No Data
US Stock MarketDetailed Quotes
RAIN Rain Oncology
Watchlist
1.040
-0.030-2.80% Close 11/29 16:00 ET
1.0400.0000.00%
Post 16:02 ET
1.080High0.990Low183.83KVolume
1.070Open1.070Pre Close190.75KTurnover1.90%Turnover RatioLossP/E (TTM)37.83MMarket Cap14.48052wk HighLossP/E (Static)36.38MShares0.82052wk Low0.56P/B10.06MFloat Cap23.900Historical High--Dividend TTM9.67MShs Float0.820Historical Low--Div YieldTTM8.41%Amplitude1.037Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Rain Oncology Company
Rain Oncology, Inc. is a clinical-stage precision oncology company, which focuses on developing and implement the precision oncology therapies for patients suffering from cancer. The company was founded by Avanish Vellanki and Robert Doebele in April 2017 and is headquartered in Newark, CA.
News
Rain Oncology Q3 EPS $(0.19) Beats $(0.27) Estimate
Rain Oncology (NASDAQ:RAIN) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.27) by 29.63 percent. This is a 72.06 percent increase over losses of $(0.68
Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
NEWARK, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN) (Rain) today reported financial results for the third quarter ended September 30, 2023, along with an update on
Rain Oncology And 3 Other Stocks Under $1 Insiders Are Buying
The Dow Jones closed slightly higher on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penn
Comments
Earnings win
$Rain Oncology(RAIN.US$ reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.27) by 29.63 percent. This is a 72.06 percent increase over losses of $(0.68) per share from the same period last year.
1
BUY OFFER ON TABLE!
$Rain Oncology(RAIN.US$ I wanted to add a bit more information from late Friday! Tang Capital Partners disclosed the proposal in an amended 13D regulatory filing on Friday.
"On behalf of Concentra Biosciences, LLC, I am pleased to submit this non-binding proposal to acquire 100% of the equity of Rain Oncology Inc. (RAIN) for $1.25 per share in cash, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition ...
"On behalf of Concentra Biosciences, LLC, I am pleased to submit this non-binding proposal to acquire 100% of the equity of Rain Oncology Inc. (RAIN) for $1.25 per share in cash, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition ...
3
Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
PYUN970IHaveChosen :